Last edition
News about "chronic myelomonocytic leukemia treatment"
Solu Therapeutics Receives FDA Fast Track Status for STX-0712 in CMML Treatment
Solu Therapeutics receives US Food and Drug Administration (FDA) Fast Track designation for STX-0712 to treat chronic myelomonocytic leukemia (CMML), supporting accelerated development for patients with relapsed or treatment-resistant disease and limited therapeutic options.
Chronic Myelomonocytic Leukemia Treatment | 28/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members